Genocea Biosciences Inc P/FCF
Что обозначает P/FCF в Genocea Biosciences Inc?
P/FCF Genocea Biosciences Inc является 0.00
Какое определение для P/FCF?
Соотношение цены и свободного денежного потока (P / FCF) является метрической оценкой, которая сравнивает текущую цену акций компании с ее свободным денежным потоком на акцию.
Price to free cash flow (P/FCF) is a measure that value investors find useful to analyze a company’s finances in relation to its current stock price. It is a stricter measure than the price to cash flow ratio as it subtracts capital expenditures from cash flow.
Free cash flow relies heavily on the state of a company's cash from operations, which is in turn heavily influenced by the company's net income. Companies can manipulate their free cash flow by lengthening the time they take to pay their bills, shortening the time it takes to collect what's owed to them, and putting off buying inventory. It also depends on what items are considered capital expenditures and this can be different in case of different companies.
Lower values of P/FCF generally indicate a company that is undervalued and whose stock is relatively cheap in relation to its free cash flow. Conversely, higher P/FCF indicate that the company's stock is relatively overvalued. Value investors thus favor companies with low or decreasing price to free cash flow values that indicate high or increasing free cash flow totals and relatively low stock share prices.
It is best to compare price to free cash flow ratios between similar companies in the same industry. However, the P/FCF metric can also be viewed over a longer time frame to see if the company's cash flow to share price value is improving or declining.
P/FCF компаний в Health Care сектор на NASDAQ по сравнению с Genocea Biosciences Inc
Что делает Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Компании с p/fcf похож на Genocea Biosciences Inc
- Genocea Biosciences Inc имеет P/FCF из 0.00
- Enel Generacion Chile S.A имеет P/FCF из 0.01
- Enel Generacion Chile S.A имеет P/FCF из 0.01
- YPF имеет P/FCF из 0.01
- Mallinckrodt plc имеет P/FCF из 0.01
- Frontier Communications имеет P/FCF из 0.01
- Monitronics International имеет P/FCF из 0.01